Cipla Limited, one of India’s top pharmaceutical companies, continues to deliver strong fundamentals and global growth. However, as we head toward the November 2025 expiry, short-term technical indicators are showing potential weakness, suggesting that traders may find an opportunity for strategic entries in the derivatives segment.
Technical View (For November 2025 Expiry):
As per the latest chart analysis, Cipla share is facing resistance around ₹1570, indicating possible profit-booking pressure at higher levels.
-
Entry Level: ₹1570
-
Stop Loss: ₹1600
-
Target Price: ₹1450
-
Expiry: November 2025
If the stock remains unable to hold above ₹1570, a correction toward ₹1450 is likely in the November 2025 expiry. Traders are advised to maintain a strict stop loss at ₹1600 to manage risk effectively. RSI and MACD are both signaling early bearish divergence, supporting the possibility of a short-term downward movement.
About Cipla Limited:
Cipla Ltd. is one of India’s most respected pharmaceutical manufacturers, recognized globally for its high-quality, affordable medicines. The company’s product range covers respiratory, cardiovascular, and anti-infective therapies, with a presence in over 80 countries. Cipla’s continuous focus on research and innovation keeps it at the forefront of the healthcare sector.
Expert Insights by Niti Neeyam Services:
Other Financial & Business Services by Niti Neeyam Services:
Along with trading support, we offer a comprehensive range of financial and compliance services, including:
-
GST Registration & Filing
-
ITR Filing (Individual & Business)
-
Auditing & Bookkeeping
-
Tally Accounting & Balance Sheet Preparation
-
Digital Signature (DSC)
-
FSSAI & Trade License Registration
-
Loans – Personal, MSME, Mudra, Home, Car & Loan Against Property
-
Insurance – Two-wheeler, Four-wheeler & General Insurance
-
Demat Account Opening & Share/Commodity/Forex Trading
Visit our official website nitineeyam.in to explore all services and subscribe for trading updates.
Disclaimer:
This blog post is for educational and informational purposes only and does not constitute financial advice. Stock market and derivative trading involve market risks. Please consult your financial advisor before making any investment or trading decisions.

0 Comments